COMPANY

Cytoagents, Inc.

HQ: Pittsburgh, PA source · cytoagents.com ↗ · Mid-Atlantic

Location: Pittsburgh, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Cytokine Release Syndrome influenza CTO1681

Funding and NIH signals

NIH award NIH awarded $936K (SBIR Phase II 5R44CA295189-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA295189-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44CA295189-02
  Organization: CYTOAGENTS, INC.; City/State: PITTSBURGH, PA; Project number: 5R44CA295189-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 936370; Administering IC: National Cancer Institute; Project title: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $936,370 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 19, 2025 Grant Government grant — SBIR: $1.31M (annual award, as published), announced Sep 19, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 15, 2025 Grant Government grant — SBIR: $1.01M (annual award, as published), announced Aug 15, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Dec 28, 2023 Trial start Phase 1/Phase 2: Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy source ↗

2027-06 (ESTIMATED) · Phase 1/Phase 2 · Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy · NCT05905328

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $936,370 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 19, 2025 Government grant — SBIR: $1.31M (annual award, as published), announced Sep 19, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 15, 2025 Government grant — SBIR: $1.01M (annual award, as published), announced Aug 15, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05905328	Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy	Phase 1/Phase 2	Recruiting	Dec 28, 2023	2027-06 (estimated)

Annual award amounts. Total $4.7M.

Sep 20, 2024 NIH award 1R44CA287634-01A1 FY2024: $994,859 awarded for that fiscal year; activity R44 (SBIR); PI BERTOLINO, ARTHUR P; recipient as written: CYTOAGENTS, INC., PITTSBURGH, PA. CTO1681 to prevent and mitigate cytokine source ↗
Mar 28, 2022 NIH award 5R44AI157719-02 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI CRAIGO, JODI K; recipient as written: CYTOAGENTS, INC., PITTSBURGH, PA. Preclinical development of an immunomodulator source ↗
Apr 15, 2021 NIH award 5R44AI152726-02 FY2021: $813,514 awarded for that fiscal year; activity R44 (SBIR); PI CRAIGO, JODI K; recipient as written: CYTOAGENTS, INC., PITTSBURGH, PA. Preclinical development of an immunomodulatory source ↗
Mar 5, 2021 NIH award 1R44AI157719-01 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI CRAIGO, JODI K; recipient as written: CYTOAGENTS, INC., PITTSBURGH, PA. Preclinical development of an immunomodulator source ↗
May 8, 2020 NIH award 1R44AI152726-01 FY2020: $848,308 awarded for that fiscal year; activity R44 (SBIR); PI CRAIGO, JODI K; recipient as written: CYTOAGENTS, INC., PITTSBURGH, PA. Preclinical development of an immunomodulatory source ↗